vs

Side-by-side financial comparison of Elme Communities (ELME) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $62.1M, roughly 1.2× Elme Communities). Health Catalyst, Inc. runs the higher net margin — -121.9% vs -198.9%, a 77.0% gap on every dollar of revenue. On growth, Elme Communities posted the faster year-over-year revenue change (1.7% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $7.2M). Over the past eight quarters, Elme Communities's revenue compounded faster (2.7% CAGR vs -0.0%).

Elme Communities is a publicly traded U.S. real estate investment trust that primarily owns, operates and develops high-quality multifamily residential communities. It focuses on key growth markets across the U.S. Mid-Atlantic and Southeast, offering affordable to mid-tier housing options for diverse renter groups.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

ELME vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.2× larger
HCAT
$74.7M
$62.1M
ELME
Growing faster (revenue YoY)
ELME
ELME
+7.9% gap
ELME
1.7%
-6.2%
HCAT
Higher net margin
HCAT
HCAT
77.0% more per $
HCAT
-121.9%
-198.9%
ELME
More free cash flow
HCAT
HCAT
$2.4M more FCF
HCAT
$9.6M
$7.2M
ELME
Faster 2-yr revenue CAGR
ELME
ELME
Annualised
ELME
2.7%
-0.0%
HCAT

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ELME
ELME
HCAT
HCAT
Revenue
$62.1M
$74.7M
Net Profit
$-123.5M
$-91.0M
Gross Margin
61.1%
Operating Margin
-183.3%
-115.3%
Net Margin
-198.9%
-121.9%
Revenue YoY
1.7%
-6.2%
Net Profit YoY
-4058.7%
-340.3%
EPS (diluted)
$-1.40
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ELME
ELME
HCAT
HCAT
Q4 25
$74.7M
Q3 25
$62.1M
$76.3M
Q2 25
$62.1M
$80.7M
Q1 25
$61.5M
$79.4M
Q4 24
$61.3M
$79.6M
Q3 24
$61.1M
$76.4M
Q2 24
$60.1M
$75.9M
Q1 24
$59.5M
$74.7M
Net Profit
ELME
ELME
HCAT
HCAT
Q4 25
$-91.0M
Q3 25
$-123.5M
$-22.2M
Q2 25
$-3.6M
$-41.0M
Q1 25
$-4.7M
$-23.7M
Q4 24
$-3.0M
$-20.7M
Q3 24
$-3.0M
$-14.7M
Q2 24
$-3.5M
$-13.5M
Q1 24
$-3.6M
$-20.6M
Gross Margin
ELME
ELME
HCAT
HCAT
Q4 25
Q3 25
61.1%
52.6%
Q2 25
63.5%
Q1 25
64.2%
Q4 24
62.9%
Q3 24
63.5%
47.5%
Q2 24
63.4%
Q1 24
63.5%
Operating Margin
ELME
ELME
HCAT
HCAT
Q4 25
-115.3%
Q3 25
-183.3%
-22.9%
Q2 25
9.6%
-46.0%
Q1 25
7.8%
-25.4%
Q4 24
10.4%
-22.0%
Q3 24
11.0%
-17.9%
Q2 24
9.8%
-20.8%
Q1 24
7.5%
-30.5%
Net Margin
ELME
ELME
HCAT
HCAT
Q4 25
-121.9%
Q3 25
-198.9%
-29.1%
Q2 25
-5.7%
-50.8%
Q1 25
-7.6%
-29.9%
Q4 24
-4.9%
-26.0%
Q3 24
-4.9%
-19.3%
Q2 24
-5.8%
-17.8%
Q1 24
-6.1%
-27.6%
EPS (diluted)
ELME
ELME
HCAT
HCAT
Q4 25
$-1.29
Q3 25
$-1.40
$-0.32
Q2 25
$-0.04
$-0.59
Q1 25
$-0.05
$-0.35
Q4 24
$-0.04
$-0.33
Q3 24
$-0.03
$-0.24
Q2 24
$-0.04
$-0.23
Q1 24
$-0.04
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ELME
ELME
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$7.1M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$908.9M
$245.8M
Total Assets
$1.7B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ELME
ELME
HCAT
HCAT
Q4 25
$95.7M
Q3 25
$7.1M
$91.5M
Q2 25
$4.8M
$97.3M
Q1 25
$6.4M
$342.0M
Q4 24
$6.1M
$392.0M
Q3 24
$4.8M
$387.3M
Q2 24
$5.6M
$308.3M
Q1 24
$4.2M
$327.8M
Total Debt
ELME
ELME
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
ELME
ELME
HCAT
HCAT
Q4 25
$245.8M
Q3 25
$908.9M
$331.9M
Q2 25
$1.0B
$347.5M
Q1 25
$1.1B
$376.8M
Q4 24
$1.1B
$365.2M
Q3 24
$1.1B
$355.0M
Q2 24
$1.1B
$357.0M
Q1 24
$1.1B
$357.2M
Total Assets
ELME
ELME
HCAT
HCAT
Q4 25
$502.6M
Q3 25
$1.7B
$587.1M
Q2 25
$1.8B
$616.2M
Q1 25
$1.8B
$891.5M
Q4 24
$1.8B
$858.9M
Q3 24
$1.9B
$813.0M
Q2 24
$1.9B
$691.7M
Q1 24
$1.9B
$695.1M
Debt / Equity
ELME
ELME
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ELME
ELME
HCAT
HCAT
Operating Cash FlowLast quarter
$15.9M
$9.9M
Free Cash FlowOCF − Capex
$7.2M
$9.6M
FCF MarginFCF / Revenue
11.6%
12.9%
Capex IntensityCapex / Revenue
14.0%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$86.7M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ELME
ELME
HCAT
HCAT
Q4 25
$9.9M
Q3 25
$15.9M
$-464.0K
Q2 25
$29.8M
$-9.0M
Q1 25
$16.2M
$280.0K
Q4 24
$95.2M
$-3.5M
Q3 24
$20.7M
$6.2M
Q2 24
$28.9M
$1.6M
Q1 24
$21.2M
$10.3M
Free Cash Flow
ELME
ELME
HCAT
HCAT
Q4 25
$9.6M
Q3 25
$7.2M
$-719.0K
Q2 25
$21.1M
$-9.2M
Q1 25
$10.5M
$-390.0K
Q4 24
$47.9M
$-3.9M
Q3 24
$8.8M
$5.5M
Q2 24
$21.0M
$1.3M
Q1 24
$7.6M
$10.1M
FCF Margin
ELME
ELME
HCAT
HCAT
Q4 25
12.9%
Q3 25
11.6%
-0.9%
Q2 25
34.1%
-11.4%
Q1 25
17.1%
-0.5%
Q4 24
78.1%
-4.9%
Q3 24
14.4%
7.2%
Q2 24
34.9%
1.7%
Q1 24
12.8%
13.5%
Capex Intensity
ELME
ELME
HCAT
HCAT
Q4 25
0.4%
Q3 25
14.0%
0.3%
Q2 25
14.0%
0.3%
Q1 25
9.2%
0.8%
Q4 24
77.4%
0.5%
Q3 24
19.4%
0.9%
Q2 24
13.1%
0.4%
Q1 24
22.9%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ELME
ELME

Residential Segment$57.7M93%
Other$4.4M7%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons